slides · global inventory
Turn
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 37,461
Current window 23,491-23,520
Pages 1,249
Rows per page 30
Beat
23,491-23,520 of 37,461
16
The slide uses a four-column layout to present key findings from a clinical trial.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
17
The slide uses a timeline-based process diagram to illustrate the clinical trial flow.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
18
The slide outlines two distinct study arms involving AB-729, VTP-300, and Nivolumab, with a primary focus on safety and reactogenicity.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
19
The slide details a licensing deal with Qilu Pharmaceutical, including financial terms and partner background.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
20
The slide uses a three-column layout to highlight key value propositions.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
21
Includes a line chart for efficacy over time and two bar charts for pharmacokinetic concentrations in plasma vs liver.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
22
Includes a disclaimer at the bottom regarding an FDA clinical hold.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
23
The slide uses two distinct chart types (dose-response curve and bar chart) to show efficacy in two different biological assays.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
24
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
25
The slide uses a biological map of the coronavirus genome to justify targeting nsp5 and nsp12.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
26
The slide highlights key therapeutic advantages of the candidate drug.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
27
Includes a checkmark indicating completion of one milestone.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
28
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
06
The slide uses a visual representation of an antibody to explain the mechanism of action (sweeping antibody, pH/Ca2+ switch, no effector function).argenx SE | Results Presentation Deck | 13 slides · argenx
Conference presentation Investor relations Beat · What Could BeLoop · Aha Moment1 hit
07
Includes a biological mechanism diagram on the left and a clinical trial roadmap on the right.argenx SE | Results Presentation Deck | 13 slides · argenx
Conference presentation Investor relations Beat · What Could Be1 hit
10
Includes a footnote regarding APMs and exchange rates.Aston Martin Lagonda | Results Presentation Deck | 16 slides · Aston Martin Lagonda
Conference presentation Investor relations Beat · Satisfaction1 hit
04
The slide uses a value-chain style flow diagram to show the disintermediation of traditional ad-tech layers.Azerion | Investor Presentation Deck | 32 slides · Azerion
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
05
Uses a value chain comparison to illustrate market inefficiency vs. Azerion's one-stop shop model.Azerion | Investor Presentation Deck | 32 slides · Azerion
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
06
Bausch Health Companies | Results Presentation Deck | 40 slidesBausch Health Companies | Results Presentation Deck | 40 slides · Bausch Health
Conference presentation Investor relations Beat · Satisfaction1 hit
07
The slide uses a three-column layout to categorize R&D projects by business unit.Bausch Health Companies | Results Presentation Deck | 40 slides · Bausch Health
Conference presentation Investor relations Beat · Satisfaction1 hit
08
Includes reported and organic growth comparisons for three business segments.Bausch Health Companies | Results Presentation Deck | 40 slides · Bausch Health
Conference presentation Investor relations Beat · SatisfactionLoop · Analogy1 hit
09
The slide uses donut charts to show revenue composition and lists reported/organic growth rates below each segment.Bausch Health Companies | Results Presentation Deck | 40 slides · Bausch Health
Conference presentation Investor relations Beat · SatisfactionLoop · Analogy1 hit
10
Bausch Health Companies | Results Presentation Deck | 40 slidesBausch Health Companies | Results Presentation Deck | 40 slides · Bausch Health
Conference presentation Investor relations Beat · SatisfactionLoop · Analogy1 hit
11
The slide uses a 2x2 grid layout to present segment-specific revenue and prescription volume growth data.Bausch Health Companies | Results Presentation Deck | 40 slides · Bausch Health
Conference presentation Investor relations Beat · SatisfactionLoop · Analogy1 hit
12
Includes non-GAAP organic growth metrics.Bausch Health Companies | Results Presentation Deck | 40 slides · Bausch Health
Conference presentation Investor relations Beat · SatisfactionLoop · Analogy1 hit
13
The table includes both GAAP and non-GAAP (organic) measures.Bausch Health Companies | Results Presentation Deck | 40 slides · Bausch Health
Conference presentation Investor relations Beat · SatisfactionLoop · Analogy1 hit
14
The table shows year-over-year changes in revenue, expenses, operating income, net loss, and cash flow.Bausch Health Companies | Results Presentation Deck | 40 slides · Bausch Health
Conference presentation Investor relations Beat · Satisfaction1 hit
07
The slide illustrates a platform architecture connecting data sources to specific R&D modules via an AI engine.BenevolentAI | Investor Presentation Deck | 13 slides · BenevolentAI
Pitch deck Investor relations Beat · Solution1 hit
05
The slide displays hardware products (Beacon, IsoSpark) and software interface.Berkeley Lights | Investor Presentation Deck | 15 slides · PhenomeX
Pitch deck Investor relations Beat · Solution1 hit
06
The slide uses a visual comparison between healthy cells (alkaline) and cancer cells (acidic) to demonstrate the selective binding mechanism.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations Beat · Solution1 hit